(0.20%) 5 110.06 points
(0.19%) 38 313 points
(0.20%) 15 960 points
(-1.16%) $82.88
(4.99%) $2.02
(0.04%) $2 348.20
(0.06%) $27.55
(4.00%) $958.95
(-0.18%) $0.933
(-0.25%) $11.00
(-0.45%) $0.797
(1.74%) $93.47
Live Chart Being Loaded With Signals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders...
Stats | |
---|---|
本日の出来高 | 14 555.00 |
平均出来高 | 24 942.00 |
時価総額 | 3.31M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $0 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.220 |
ATR14 | $0.0610 (2.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-29 | Singh Vanila | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Shah Vinay | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Jambulingam Thani | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Mathias Sheila | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Dubin Michael F | Buy | 25 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
75.05 |
Last 71 transactions |
Buy: 2 396 200 | Sell: 387 701 |
Virpax Pharmaceuticals, 相関
10 最も正の相関 | |
---|---|
XBIO | 0.884 |
TRIP | 0.875 |
LTRPA | 0.868 |
SCWX | 0.852 |
SVAC | 0.851 |
GOODM | 0.845 |
MIND | 0.832 |
YTEN | 0.832 |
PRPO | 0.829 |
NVFY | 0.824 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Virpax Pharmaceuticals, 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-12.97 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-18.32 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Virpax Pharmaceuticals,
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。